JP2023549342A - 個別化されたがんワクチンのためのネオアンチゲンの選択 - Google Patents

個別化されたがんワクチンのためのネオアンチゲンの選択 Download PDF

Info

Publication number
JP2023549342A
JP2023549342A JP2023527473A JP2023527473A JP2023549342A JP 2023549342 A JP2023549342 A JP 2023549342A JP 2023527473 A JP2023527473 A JP 2023527473A JP 2023527473 A JP2023527473 A JP 2023527473A JP 2023549342 A JP2023549342 A JP 2023549342A
Authority
JP
Japan
Prior art keywords
tumor
cancer
specific
subject
neoantigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549342A5 (https=
JPWO2022098936A5 (https=
Inventor
ヘッカーマン デイヴィッド
ウィルヘルム シュミッツ フランク
ヴォーグルソン マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amazon Technologies Inc
Original Assignee
Amazon Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amazon Technologies Inc filed Critical Amazon Technologies Inc
Publication of JP2023549342A publication Critical patent/JP2023549342A/ja
Publication of JP2023549342A5 publication Critical patent/JP2023549342A5/ja
Publication of JPWO2022098936A5 publication Critical patent/JPWO2022098936A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Data Mining & Analysis (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Bioethics (AREA)
  • Evolutionary Computation (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023527473A 2020-11-06 2021-11-05 個別化されたがんワクチンのためのネオアンチゲンの選択 Pending JP2023549342A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110711P 2020-11-06 2020-11-06
US63/110,711 2020-11-06
PCT/US2021/058162 WO2022098936A1 (en) 2020-11-06 2021-11-05 Selecting neoantigens for personalized cancer vaccine

Publications (3)

Publication Number Publication Date
JP2023549342A true JP2023549342A (ja) 2023-11-24
JP2023549342A5 JP2023549342A5 (https=) 2024-11-12
JPWO2022098936A5 JPWO2022098936A5 (https=) 2024-11-12

Family

ID=78695860

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527473A Pending JP2023549342A (ja) 2020-11-06 2021-11-05 個別化されたがんワクチンのためのネオアンチゲンの選択

Country Status (5)

Country Link
US (1) US20230197192A1 (https=)
EP (1) EP4241274A1 (https=)
JP (1) JP2023549342A (https=)
CN (1) CN116802738A (https=)
WO (1) WO2022098936A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024508677A (ja) * 2021-02-05 2024-02-28 アマゾン テクノロジーズ インコーポレイテッド 個別化がんワクチン用ネオアンチゲンのランク付け

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025128926A1 (en) 2023-12-13 2025-06-19 Amazon Technologies, Inc. Methods of identifying and treating individuals with elevated cancer risk
US20250197924A1 (en) 2023-12-15 2025-06-19 Amazon Technologies, Inc. Methods for selection and combination of sequencing results from biological samples for neoantigen scoring
WO2026073127A1 (en) 2024-09-30 2026-04-02 Amazon Technologies, Inc. Dual assay to boost accuracy of detected actionable variants in liquid biopsy
WO2026072916A1 (en) 2024-09-30 2026-04-02 Amazon Technologies, Inc. Structural variant detection in circulating tumor dna

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015531240A (ja) * 2012-10-09 2015-11-02 ファイブ３・ジェノミクス・エルエルシーＦｉｖｅ３ Ｇｅｎｏｍｉｃｓ， Ｌｌｃ 腫瘍クローン性解析のためのシステムおよび方法
JP2019501967A (ja) * 2015-12-16 2019-01-24 グリットストーン オンコロジー インコーポレイテッド 新生抗原の特定、製造、および使用
WO2019050994A1 (en) * 2017-09-05 2019-03-14 Gritstone Oncology, Inc. IDENTIFICATION OF NEOANTIGEN FOR LYMPHOCYTE THERAPY T
WO2020065023A1 (en) * 2018-09-27 2020-04-02 Vaccibody As Method for selecting neoepitopes
WO2020132586A1 (en) * 2018-12-21 2020-06-25 Neon Therapeutics, Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
US10364468B2 (en) * 2016-01-13 2019-07-30 Seven Bridges Genomics Inc. Systems and methods for analyzing circulating tumor DNA
EP3652318A1 (en) * 2017-07-11 2020-05-20 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015531240A (ja) * 2012-10-09 2015-11-02 ファイブ３・ジェノミクス・エルエルシーＦｉｖｅ３ Ｇｅｎｏｍｉｃｓ， Ｌｌｃ 腫瘍クローン性解析のためのシステムおよび方法
JP2019501967A (ja) * 2015-12-16 2019-01-24 グリットストーン オンコロジー インコーポレイテッド 新生抗原の特定、製造、および使用
WO2019050994A1 (en) * 2017-09-05 2019-03-14 Gritstone Oncology, Inc. IDENTIFICATION OF NEOANTIGEN FOR LYMPHOCYTE THERAPY T
WO2020065023A1 (en) * 2018-09-27 2020-04-02 Vaccibody As Method for selecting neoepitopes
WO2020132586A1 (en) * 2018-12-21 2020-06-25 Neon Therapeutics, Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024508677A (ja) * 2021-02-05 2024-02-28 アマゾン テクノロジーズ インコーポレイテッド 個別化がんワクチン用ネオアンチゲンのランク付け

Also Published As

Publication number Publication date
US20230197192A1 (en) 2023-06-22
CN116802738A (zh) 2023-09-22
EP4241274A1 (en) 2023-09-13
WO2022098936A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
US20210262039A1 (en) Molecular biomarkers for cancer immunotherapy
JP2023549342A (ja) 個別化されたがんワクチンのためのネオアンチゲンの選択
CA2797868C (en) Compositions and methods of identifying tumor specific neoantigens
US20240269179A1 (en) Neoantigens as targets for immunotherapy
JP7060324B2 (ja) ネオ抗原ワクチンによる併用療法
CN112534045A (zh) 获得肿瘤特异性t细胞受体的方法
JP2019513021A (ja) ネオエピトープ提示のための配列の配置および配列
JP7034931B2 (ja) ネオエピトープのウイルス送達のための改善された組成物および方法ならびにその使用
CN108700592A (zh) 新表位的迭代发现及其适应性免疫疗法和方法
JP2024508677A (ja) 個別化がんワクチン用ネオアンチゲンのランク付け
RS62390B1 (sr) Izbor neoepitopa kao ciljeva specifičnih za bolest za terapiju sa povećanom efikasnošću
JP2019509265A (ja) 二重標的化によるアデノウイルスの皮下送達
IL266728A (en) Detection of recurrent mutant neopeptides
CN115485395A (zh) 用于治疗癌症的包含剪接-衍生的抗原的组合物和方法
JP2024512462A (ja) 不均一な悪性腫瘍についての腫瘍ワクチン抗原カバレッジを最適化するための方法
US20220389102A1 (en) Hla class i sequence divergence and cancer therapy
AU2021205080B2 (en) Compositions and methods of identifying tumor specific neoantigens
CN112533630A (zh) 用于癌症的个体化疫苗
CN119486753A (zh) 个体化癌症表位及其使用方法
WO2023064883A1 (en) Immunotherapeutic methods for treating cancer
JP2024534442A (ja) ネオ抗原アジュバント及び維持療法
US20250003004A1 (en) Personalized Longitudinal Analysis of Circulating Material to Monitor and Adapt Neoantigen Cancer Vaccines
CN118302188A (zh) 新抗原辅助和维持治疗
CN119907681A (zh) 使用新生抗原疫苗的组合疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260227